Physician profile
Laura E Smith
NPI 1235477324
$1,855.67
in general payments reported to CMS, 2019-2025
17 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $399 · 2023: $234 · 2024: $377 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $230.16 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $208.65 | 2021-2025 | Ilumya |
| Genzyme Corporation | $170.77 | 2021-2025 | |
| Janssen Biotech, INC. | $91.38 | 2023-2024 | Tremfya |
| Pfizer INC. | $74.29 | 2021-2025 | |
| Incyte Corporation | $40.78 | 2024-2025 | Opzelura |
| Almirall LLC | $37.40 | 2022-2023 | Klisyri |
| Lilly USA, LLC | $36.33 | 2022-2023 | Taltz, Olumiant |
| Amgen INC. | $28.26 | 2024 | Otezla |
| Organon LLC | $28.06 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.50 | 2025 | |
| Dermira, INC. | $25.83 | 2021 | |
| Leo Pharma INC. | $25.66 | 2021 | |
| Botanix Sb INC | $23.61 | 2025 | Sofdra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $20.61 | 2024 | |
| Galderma Laboratories, L.P. | $14.75 | 2024 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.